Document Type

Article

Publication Date

4-27-2026

Comments

This article is the author’s final published version in Gastroenterology Research, Volume 19, Issue 2, 2026, Pages 64-73.

The published version is available at https://doi.org/10.14740/gr2108. Copyright © The authors.

Abstract

BACKGROUND: The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has remarkably increased in the past few years as they have demonstrated significant reduction in A1c and major cardiovascular outcomes and have led to weight loss with low risk of hypoglycemia. GLP-1 RA use has raised concerns about potential associations with increased gastric retention and adverse outcomes in upper endoscopy procedures.

METHODS: We conducted a comprehensive search across multiple databases to identify comparative studies evaluating the impact of GLP-1 RA exposure versus non-exposure on upper endoscopy outcomes. Studies comparing GLP-1 RAs to other medications were excluded. The primary outcome was the presence of retained gastric contents, with secondary outcomes including aspiration risk and the need for repeated esophagogastroduodenoscopy (EGD).

RESULTS: Our systematic review included 28 studies, comprising data from 212,082 individuals collected between 2015 and 2023. The meta-analysis revealed that GLP-1 RA use was associated with approximately four times higher odds of retained gastric contents compared to non-exposure (odds ratio (OR): 3.95, confidence interval (CI): 2.691-5.815, P < 0.0001, I2: 82.71%). There were no increased odds of aspiration (OR: 1.09, CI: 0.459-2.600, P = 0.145, I2: 91.44%) or repeated upper endoscopies (OR: 1.82, CI: 0.813-4.085, P = 0.145, I2: 85.32%). However, GLP-1 RA use was significantly associated with increased odds of procedure cancellation (OR: 3.96, CI: 2.870-5.563, P < 0.0001, I2: 4.19%).

CONCLUSION: While GLP-1 RAs do not increase the risk of aspiration or necessitate repeated procedures, they are linked to a higher incidence of retained gastric contents and procedure cancellations. Further randomized controlled trials are necessary to better understand the effects of GLP-1 RAs on upper endoscopy outcomes.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

PubMed ID

42137745

Language

English

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.